Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9208648rdf:typepubmed:Citationlld:pubmed
pubmed-article:9208648lifeskim:mentionsumls-concept:C1280551lld:lifeskim
pubmed-article:9208648lifeskim:mentionsumls-concept:C0031327lld:lifeskim
pubmed-article:9208648lifeskim:mentionsumls-concept:C0027360lld:lifeskim
pubmed-article:9208648lifeskim:mentionsumls-concept:C0355800lld:lifeskim
pubmed-article:9208648lifeskim:mentionsumls-concept:C0812407lld:lifeskim
pubmed-article:9208648pubmed:issue4lld:pubmed
pubmed-article:9208648pubmed:dateCreated1997-8-4lld:pubmed
pubmed-article:9208648pubmed:abstractTextPharmacokinetics of naltrexone hydrochloride (NTX) and naltrexone glucuronide was studied in the dog using HPLC-electrochemical detection with naloxone as internal standard. After iv 5 mg or po 10 mg NTX, the plasma concentration-time curves of NTX were found to fit to a two-compartment model and a single compartment with first-order absorption. The elimination half-lives of NTX were 78 +/- 6 min and 74 +/- 6 min, respectively. Although NTX could be absorbed rapidly in the dog after po administration, the plasma concentration of the parent drug was very low and its absolute bioavailability was 15.8%. The experiments showed that the major metabolite of NTX in dog plasma was beta-glucuronidase-hydrolyzable conjugate. Dosing NTX intravenously and orally, the plasma levels of the conjugate were 1.3 and 23 times as high as that of the parent drug, the elimination half-lives of the glucuronide from plasma were 3.4 h and 12.6 h, respectively. The results indicate that NTX is subjected to a marked first-pass effect in the dog after oral administration.lld:pubmed
pubmed-article:9208648pubmed:languagechilld:pubmed
pubmed-article:9208648pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9208648pubmed:citationSubsetIMlld:pubmed
pubmed-article:9208648pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9208648pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9208648pubmed:statusMEDLINElld:pubmed
pubmed-article:9208648pubmed:issn0513-4870lld:pubmed
pubmed-article:9208648pubmed:authorpubmed-author:WaniHHlld:pubmed
pubmed-article:9208648pubmed:authorpubmed-author:LiHHlld:pubmed
pubmed-article:9208648pubmed:authorpubmed-author:GeZ HZHlld:pubmed
pubmed-article:9208648pubmed:authorpubmed-author:ZhaoS FSFlld:pubmed
pubmed-article:9208648pubmed:issnTypePrintlld:pubmed
pubmed-article:9208648pubmed:volume31lld:pubmed
pubmed-article:9208648pubmed:ownerNLMlld:pubmed
pubmed-article:9208648pubmed:authorsCompleteYlld:pubmed
pubmed-article:9208648pubmed:pagination254-7lld:pubmed
pubmed-article:9208648pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:9208648pubmed:meshHeadingpubmed-meshheading:9208648-...lld:pubmed
pubmed-article:9208648pubmed:meshHeadingpubmed-meshheading:9208648-...lld:pubmed
pubmed-article:9208648pubmed:meshHeadingpubmed-meshheading:9208648-...lld:pubmed
pubmed-article:9208648pubmed:meshHeadingpubmed-meshheading:9208648-...lld:pubmed
pubmed-article:9208648pubmed:meshHeadingpubmed-meshheading:9208648-...lld:pubmed
pubmed-article:9208648pubmed:meshHeadingpubmed-meshheading:9208648-...lld:pubmed
pubmed-article:9208648pubmed:meshHeadingpubmed-meshheading:9208648-...lld:pubmed
pubmed-article:9208648pubmed:meshHeadingpubmed-meshheading:9208648-...lld:pubmed
pubmed-article:9208648pubmed:meshHeadingpubmed-meshheading:9208648-...lld:pubmed
pubmed-article:9208648pubmed:year1996lld:pubmed
pubmed-article:9208648pubmed:articleTitle[Pharmacokinetics of naltrexone hydrochloride and naltrexone glucuronide in the dog].lld:pubmed
pubmed-article:9208648pubmed:affiliationInstitute of Pharmacology and Toxicology, Academy of Military Medical Sciences, Beijing.lld:pubmed
pubmed-article:9208648pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9208648pubmed:publicationTypeEnglish Abstractlld:pubmed